Report cover image

Short Bowel Syndrome Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20147047

Description

Short bowel syndrome is a rare condition characterized by insufficient small bowel length, typically less than 180–200 cm in adults. The disease affects approximately 1-2 per 100,000 individuals annually. Current treatment options, such as parenteral nutrition, fail to fully address the clinical needs of patients with short bowel syndrome, creating a significant unmet need for more effective therapies. With ongoing advancements in biologics, regenerative medicine, and surgical interventions, there is growing hope for improved treatment options. Additionally, the increasing focus on personalized medicine and precision therapies is expected to drive pipeline growth in the coming years, offering potential breakthroughs for managing short bowel syndrome.

Report Coverage

The Short Bowel Syndrome Drug Pipeline Insight Report by Expert Market Research provides comprehensive insights into short bowel syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for short bowel syndrome. The short bowel syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The short bowel syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with short bowel syndrome treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to short bowel syndrome.

Short Bowel Syndrome Drug Pipeline Outlook

Short bowel syndrome is a malabsorptive disorder that occurs when a significant portion of the small intestine is surgically removed or damaged, typically due to conditions such as Crohn’s disease, trauma, or cancer. This leads to inadequate nutrient absorption, resulting in malnutrition and dehydration.

Short bowel syndrome treatment focuses on managing symptoms and improving nutrient absorption. Common options include parenteral nutrition, enteral feeding, and medications such as glutamine or teduglutide. In severe cases, small bowel transplantation may be considered for patients with a poor prognosis.

Short Bowel Syndrome Epidemiology

A 2024 study on short bowel syndrome revealed the global prevalence to be approximately 1 to 2 cases per 100,000 individuals annually. In the United States, the incidence ranges from 0.3 to 4 cases per 100,000 inhabitants, while in Europe, it varies between 0.1 and 4 cases per 100,000. These findings highlight the rare but significant impact of short bowel syndrome on affected populations.

Short Bowel Syndrome Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of short bowel syndrome drug candidates based on several segmentations, including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Cell Therapies
  • Peptides
  • Others
By Route of Administration
  • Oral
  • Parenteral
  • Others
Short Bowel Syndrome Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase III covers a major share of the total short bowel syndrome clinical trials.

Short Bowel Syndrome – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the short bowel syndrome pipeline analysis include cell therapies, peptides, and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for short bowel syndrome.

Short Bowel Syndrome Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the short bowel syndrome report insights includes the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in short bowel syndrome clinical trials:
  • Chongqing Peg-Bio Biopharm Co., Ltd.
  • VectivBio AG
  • Hanmi Pharmaceutical Company Limited
  • Zealand Pharma
  • Napo Pharmaceuticals, Inc.
Short Bowel Syndrome Emerging Drugs Profile

This section covers a detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for short bowel syndrome. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of short bowel syndrome drug candidates.

Drug: Apraglutide

Sponsored by VectivBio AG, the Phase 3 study aims to evaluate the long-term safety and tolerability of apraglutide in patients with short bowel syndrome. The study, involving 158 participants, will assess the drug's safety, efficacy, and durability over up to 208 weeks. The study’s completion is anticipated by October 2027.

Drug: Amoxicillin, Levofloxacin, Ofloxacin, Sulfamethoxazole-Trimethoprim

The clinical trial, sponsored by Central Hospital, Nancy, France, aims to assess the absorption of oral antibiotics, including amoxicillin, levofloxacin, ofloxacin, and sulfamethoxazole-trimethoprim, in patients with short bowel syndrome. The Phase 1 study is expected to be completed by February 2025 and will involve 10 participants, evaluating the pharmacokinetic profiles of these antibiotics.

Reasons To Buy This Report

The Short Bowel Syndrome Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for short bowel syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. Stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within short bowel syndrome pipeline insights.

Key Questions Answered in the Short Bowel Syndrome – Pipeline Insight Report
  • What is the current landscape of short bowel syndrome pipeline drugs?
  • Which companies/institutions are developing short bowel syndrome emerging drugs?
  • How many phase II drugs are currently present in short bowel syndrome pipeline drugs?
  • Which company is leading the short bowel syndrome pipeline development activities?
  • What is the current short bowel syndrome therapeutic assessment?
  • What are the opportunities and challenges present in the short bowel syndrome drug pipeline landscape?
  • What is the efficacy and safety profile of short bowel syndrome pipeline drugs?
  • Which companies/institutions are involved in short bowel syndrome collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in short bowel syndrome?
Related Reports

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Short Bowel Syndrome
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Short Bowel Syndrome
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Short Bowel Syndrome: Epidemiology Snapshot
5.1 Short Bowel Syndrome Incidence by Key Markets
5.2 Short Bowel Syndrome – Patients Seeking Treatment in Key Markets
6 Short Bowel Syndrome: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Short Bowel Syndrome: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Short Bowel Syndrome, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Short Bowel Syndrome Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Short Bowel Syndrome Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Apraglutide
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: PJ009
10.2.3 Other Drugs
11 Short Bowel Syndrome Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: HM15912 Active
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Other Drugs
12 Short Bowel Syndrome Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: Amoxicillin, Levofloxacin, Ofloxacin, Sulfamethoxazole Trimethoprim
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Short Bowel Syndrome Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug: Crofelemer Oral Product
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Short Bowel Syndrome, Key Drug Pipeline Companies
14.1 Chongqing Peg-Bio Biopharm Co., Ltd.
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 VectivBio AG
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Hanmi Pharmaceutical Company Limited
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Zealand Pharma
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Napo Pharmaceuticals, Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us